These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 37419638)
1. Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial. Hutchins H; Bradley J; Pretorius E; Teixeira da Silva E; Vasileva H; Jones RT; Ndiath MO; Dit Massire Soumare H; Mabey D; Nante EJ; Martins C; Logan JG; Slater H; Drakeley C; D'Alessandro U; Rodrigues A; Last AR BMJ Open; 2023 Jul; 13(7):e072347. PubMed ID: 37419638 [TBL] [Abstract][Full Text] [Related]
2. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. McLean ARD; Indrasuta C; Khant ZS; Phyo AK; Maung SM; Heaton J; Aung H; Aung Y; Soe K; Swe MMM; von Seidlein L; Tun NN; Tun KM; Day NPJ; Ashley EA; Hlaing T; Kyaw TT; Dondorp AM; Imwong M; White NJ; Smithuis FM Lancet Infect Dis; 2021 Nov; 21(11):1579-1589. PubMed ID: 34147154 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Slater HC; Foy BD; Kobylinski K; Chaccour C; Watson OJ; Hellewell J; Aljayyoussi G; Bousema T; Burrows J; D'Alessandro U; Alout H; Ter Kuile FO; Walker PGT; Ghani AC; Smit MR Lancet Infect Dis; 2020 Apr; 20(4):498-508. PubMed ID: 31948767 [TBL] [Abstract][Full Text] [Related]
5. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Dabira ED; Soumare HM; Conteh B; Ceesay F; Ndiath MO; Bradley J; Mohammed N; Kandeh B; Smit MR; Slater H; Peeters Grietens K; Broekhuizen H; Bousema T; Drakeley C; Lindsay SW; Achan J; D'Alessandro U Lancet Infect Dis; 2022 Apr; 22(4):519-528. PubMed ID: 34919831 [TBL] [Abstract][Full Text] [Related]
6. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. von Seidlein L; Peto TJ; Landier J; Nguyen TN; Tripura R; Phommasone K; Pongvongsa T; Lwin KM; Keereecharoen L; Kajeechiwa L; Thwin MM; Parker DM; Wiladphaingern J; Nosten S; Proux S; Corbel V; Tuong-Vy N; Phuc-Nhi TL; Son DH; Huong-Thu PN; Tuyen NTK; Tien NT; Dong LT; Hue DV; Quang HH; Nguon C; Davoeung C; Rekol H; Adhikari B; Henriques G; Phongmany P; Suangkanarat P; Jeeyapant A; Vihokhern B; van der Pluijm RW; Lubell Y; White LJ; Aguas R; Promnarate C; Sirithiranont P; Malleret B; Rénia L; Onsjö C; Chan XH; Chalk J; Miotto O; Patumrat K; Chotivanich K; Hanboonkunupakarn B; Jittmala P; Kaehler N; Cheah PY; Pell C; Dhorda M; Imwong M; Snounou G; Mukaka M; Peerawaranun P; Lee SJ; Simpson JA; Pukrittayakamee S; Singhasivanon P; Grobusch MP; Cobelens F; Smithuis F; Newton PN; Thwaites GE; Day NPJ; Mayxay M; Hien TT; Nosten FH; Dondorp AM; White NJ PLoS Med; 2019 Feb; 16(2):e1002745. PubMed ID: 30768615 [TBL] [Abstract][Full Text] [Related]
7. Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial. Soumare HM; Dabira ED; Camara MM; Jadama L; Gaye PM; Kanteh S; Jawara EA; Njie AK; Sanneh F; Ndiath MO; Lindsay SW; Conteh B; Ceesay S; Mohammed N; Ooko M; Bradley J; Drakeley C; Erhart A; Bousema T; D'Alessandro U Parasit Vectors; 2022 Nov; 15(1):435. PubMed ID: 36397132 [TBL] [Abstract][Full Text] [Related]
8. Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial. Ursing J; Rombo L; Rodrigues A; Kofoed PE PLoS One; 2016; 11(9):e0161495. PubMed ID: 27649561 [TBL] [Abstract][Full Text] [Related]
9. Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial. Dabira ED; Soumare HM; Lindsay SW; Conteh B; Ceesay F; Bradley J; Kositz C; Broekhuizen H; Kandeh B; Fehr AE; Nieto-Sanchez C; Ribera JM; Peeters Grietens K; Smit MR; Drakeley C; Bousema T; Achan J; D'Alessandro U JMIR Res Protoc; 2020 Nov; 9(11):e20904. PubMed ID: 33211022 [TBL] [Abstract][Full Text] [Related]
10. Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study). Lake SJ; Phelan SL; Engelman D; Sokana O; Nasi T; Boara D; Gorae C; Schuster T; Grobler AC; Osti MH; Andrews R; Marks M; Whitfeld MJ; Romani L; Kaldor J; Steer A BMJ Open; 2020 Aug; 10(8):e037305. PubMed ID: 32868360 [TBL] [Abstract][Full Text] [Related]
11. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Smit MR; Ochomo EO; Aljayyoussi G; Kwambai TK; Abong'o BO; Chen T; Bousema T; Slater HC; Waterhouse D; Bayoh NM; Gimnig JE; Samuels AM; Desai MR; Phillips-Howard PA; Kariuki SK; Wang D; Ward SA; Ter Kuile FO Lancet Infect Dis; 2018 Jun; 18(6):615-626. PubMed ID: 29602751 [TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962 [TBL] [Abstract][Full Text] [Related]
13. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Tripura R; Peto TJ; Chea N; Chan D; Mukaka M; Sirithiranont P; Dhorda M; Promnarate C; Imwong M; von Seidlein L; Duanguppama J; Patumrat K; Huy R; Grobusch MP; Day NPJ; White NJ; Dondorp AM Clin Infect Dis; 2018 Aug; 67(6):817-826. PubMed ID: 29522113 [TBL] [Abstract][Full Text] [Related]
14. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Pongvongsa T; Phommasone K; Adhikari B; Henriques G; Chotivanich K; Hanboonkunupakarn B; Mukaka M; Peerawaranun P; von Seidlein L; Day NPJ; White NJ; Dondorp AM; Imwong M; Newton PN; Singhasivanon P; Mayxay M; Pukrittayakamee S Malar J; 2018 Nov; 17(1):405. PubMed ID: 30390647 [TBL] [Abstract][Full Text] [Related]
15. Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau. Moss S; Mańko E; Vasileva H; Da Silva ET; Goncalves A; Osborne A; Phelan J; Rodrigues A; Djata P; D'Alessandro U; Mabey D; Krishna S; Last A; Clark TG; Campino S Sci Rep; 2023 Apr; 13(1):6311. PubMed ID: 37072433 [TBL] [Abstract][Full Text] [Related]
16. Mass drug administration for malaria. Shah MP; Hwang J; Choi L; Lindblade KA; Kachur SP; Desai M Cochrane Database Syst Rev; 2021 Sep; 9(9):CD008846. PubMed ID: 34585740 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial. Kositz C; Vasileva H; Mohammed N; Achan J; Dabira ED; D'Alessandro U; Bradley J; Marks M Malar J; 2024 Feb; 23(1):54. PubMed ID: 38383367 [TBL] [Abstract][Full Text] [Related]
18. Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia. Eisele TP; Bennett A; Silumbe K; Finn TP; Porter TR; Chalwe V; Hamainza B; Moonga H; Kooma E; Chizema Kawesha E; Kamuliwo M; Yukich JO; Keating J; Schneider K; Conner RO; Earle D; Slutsker L; Steketee RW; Miller JM Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):7-18. PubMed ID: 32618247 [TBL] [Abstract][Full Text] [Related]
19. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. Foy BD; Some A; Magalhaes T; Gray L; Rao S; Sougue E; Jackson CL; Kittelson J; Slater HC; Bousema T; Da O; Coulidiaty AGV; Colt M; Wade M; Richards K; Some AF; Dabire RK; Parikh S JMIR Res Protoc; 2023 Mar; 12():e41197. PubMed ID: 36939832 [TBL] [Abstract][Full Text] [Related]
20. Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent Stone W; Mahamar A; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Youssouf A; Diallo M; Soumare HM; Kaur H; Lanke K; Ter Heine R; Bradley J; Issiaka D; Diawara H; Traore SF; Bousema T; Drakeley C; Dicko A Lancet Microbe; 2022 Jan; 3(1):e41-e51. PubMed ID: 35028628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]